Showing 126–150 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Е. М. Жукова, Yana Batyrshina
… effects of bedaquiline and fluoroquinolone-based treatment regimens in patients with MDR/XDR-TB on QT prolongation <b>Methods:</b> A prospective cohort study including 87 patients was conducted. All patients underwent a standard ECG prior to adding bedaquiline to the chemotherap…
T.I. Danilova, Yu.V. Korneev, D.А. Kudlаy, N. Yu. Nikolenko
…bjective of the study is to assess outcomes of chemotherapy regimens containing bedaquiline in patients with MDR/XDR TB including those with concurrent HIV infection. Subjects and methods . The efficacy and safety of the regimes containing bedaquiline were assessed in the intensi…
О.С. Шевченко, L.D. Todoriko, R.S. Shevchenko, S.L. Matvyeyeva, І.А. Овчаренко, et al.
…d the spectrum of drug resistance, as well as the treatment regimens in patients with pulmonary tuberculosis. Materials and methods. This study included 100 patients with pulmonary tuberculosis, divided into two groups: Group 1 (n = 52) with drug-susceptible tuberculosis and Grou…
Shi L, Gao J, Gao M, Deng P, Chen S, et al.
Introduction Diabetes mellitus (DM), a common tuberculosis (TB) comorbidity, is associated with delayed bacillary clearance during anti-TB treatment and unfavorable outcomes. Bedaquiline (BDQ), when used as part of multidrug regimen for multidrug-resistant/extensively drug-resist…
Yulia Khokhlova, М. Ф. Губкина, Natalya Yukhimenko, I. Yu. Petrаkovа, С. С. Стерликова
Relevance Chemotherapy regimens for the treatment of multi- or extensively drug resistant TB (MDR/XDR TB) include fluoroquinolones, which have age restrictions on the use. To decide on the safety of fluoroquinolones in pediatric TB, it is important to assess benefits versus risks…
Richard T. Ellison
Current management of extensively drug-resistant tuberculosis (XDR-TB) infections having resistance to agents including isoniazid, rifampin,
PIOTR K. YABLONSKY, Анна Старшинова, MIKHAIL M. NAZARENKO, E. N. Belyaeva, A. L. Chuzhov, et al.
Introduction: Improving the effectiveness of treatment of the most difficult category of patients with extensively drug-resistant tuberculosis is still relevant in the present circumstances. Efficacy of therapy is not higher than 35,7%. New therapy regimes with the use of bedaqui…
Л. В. Панова, E. A. Krushinskaya, E. S. Ovsyankinа, М. М. Авербах, Т. Г. Смирнова, et al.
Background. The effectiveness of treatment for multidrug-resistant (MDR)/pre-extensively drug-resistant (pre-XDR) TB directly depends on the tolerability of chemotherapy, including linezolid, a group A drug. Aim: To study the incidence and types of adverse drug reactions (ADRs) t…
Brit Häcker, Nicolas Schönfeld, David Krieger, Ralf Otto-Knapp, Norbert Hittel, et al.
Drug-resistant tuberculosis (DR-TB) is an ongoing challenge for patients and healthcare systems. The World Health Organization (WHO) estimated 484 000 (CI: 417 000–556 000) new multidrug-resistant/rifampicin-resistant tuberculosis (MDR-/RR-TB) cases for 2018 [1]. While new and re…
David Kajoba Mumena, Geoffrey Kwenda, Caroline Ngugi, Andrew Nyerere
Drug-Resistant Tuberculosis (DR-TB) causes high mortality and morbidity rates globally. DR-TB and COVID-19 pandemic are posing a major risk to global public health and economic security, and are jeopardizing efforts in the control, prevention and elimination of TB globally. Mycob…
World Health Organization. Regional Office for Europe, Zhurkin D, Gupta R K, Gadoev J, Dadu A, et al.
Jeongha Mok, Hyungseok Kang, Won‐Jung Koh, Byung Woo Jhun, Jae‐Joon Yim, et al.
<b>The optimised use of delamanid combined with effective repurposed drugs could achieve a high treatment success rate, even in pre-extensively drug-resistant (XDR)-TB and XDR-TB patients</b>http://bit.ly/2plvEOT
Paikray E, Pattnaik M, Mishra V, Abhisek PA, Pradhan SS, et al.
Background The foremost concern and challenge in managing drug-resistant tuberculosis is ensuring a high health-related quality of life (HRQoL). The effectiveness of pre-extensively drug-resistant (Pre-XDR) tuberculosis management hinges on patients adhering to therapy, a crucial…
Fadeyi MO, Decroo T, Ortuño-Gutiérrez N, Ahmed B, Jinadu A, et al.
Background Patients with TB resistant to rifampicin (Rr-TB), and those with additional resistance to fluoroquinolones (pre-XDR-TB), should be treated with bedaquiline-pretomanid-linezolid-moxifloxacin and bedaquiline-pretomanid-linezolid, respectively. However, pretomanid is not …
Olayanju O, Esmail A, Limberis J, Gina P, Dheda K
Background Treatment outcomes of patients with extensively drug-resistant tuberculosis (XDR-TB) are suboptimal and treatment options remain limited. Linezolid is associated with improved outcomes but also substantial toxicity, and details about the relationship between these are …
Zarir F Udwadia, Jigneshkumar M. Patel
…ected to long, expensive, toxic and painful injection-based regimens. These regimens had been adopted despite sub-optimal evidence and without any RCTs to support their use. Little wonder then that global treatment success rates were only 60% for MDR-TB in 2019.[1] Over the last …
Charles Horsburgh, MD, Payam Nahid, MD
…rculosis (XDR-TB).(1) Current WHO-endorsed MDR-TB treatment regimens take 9-20 months to complete and are associated with substantial toxicity, including deafness from injectable agents, hepatitis from pyrazinamide and severe neuropathy from linezolid. Given the long duration and…
Keertan Dheda, MD/PhD
…-infected participants already on alternative ARV treatment regimens will be changed to the above-mentioned regimen. (v) Participants whose MDR-TB treatment has failed: In the conventional arm, management of failed MDR-TB treatment will be as per the NTP guidelines (with guidanc…
Prof Tubonye Harry, Dimie Ogoina, Dr Peter Nwakile, P. Ikuabe, Mr Jonathan Nanakede, et al.
shorter regimens, and 7 (13,2%) -with longer regimens (p < 0.05).Treatment outcomes were not evaluated in 6 patients (10,3%) who had started on shorter regimens and in 9 (17.0%)-on longer regimens (p > 0.05).One patient (1,7%) in the short regimen group died of TB and 2 (3.8%) in…
Francesca M Conradie
…ones were moved to Category A and should be included in all regimens as core drugs. CFZ and terizidone as Category B drugs, should be added to all regimens. The current short injectable-free treatment regimen for RR-TB in South Africa is based on these WHO recommendations. This …
Olatunde Olayanju
…stant (XDR) TB patients who received programmatic treatment regimens with the backbone of second line injectables and fluoroquinolones (nonbedaquiline-based) and those who received a bedaquiline- and/ or linezolid-based treatment regimen. The second study determined the frequency…
Marjorie Z. Imperial
…ess severe. Shorter, efficacious, and better-tolerated oral regimens for TB are needed. Unfortunately, all recent Phase 3 clinical trials aimed to shorten treatment duration from 6 months to 4 months for drug susceptible TB failed. The aims of this dissertation were to quantitive…
Rajendra Prasad, Harsh Saxena, Nikhil Gupta, Mohammad Tanzeem, Ronal Naorem1
…have now choice of two types of regimen, shorter and longer regimens. Shorter regimen for treatment of subset of MDR-TB patients who have not been previously treated with second line drugs and in whom resistance to fluoroquinolones and second-line injectable agents has been exclu…
Rahnuma Ahmad, Susmita Sinha, Kona Chowdhury, Mainul Haque
…90 and 60 years, respectively.[9] Antitubercular medication regimens require a minimum of 6–24 months of medication with rifampicin and three more drugs, such as isoniazid (INH), pyrazinamide and ethambutol, depending on individual clinical need.[10-12] The 6-month regimen for TB…
David S.C. Hui, Chi Chiu Leung
…imited to guide the formulation of individualized treatment regimens for MDR-/rifampicin-resistant (RR-)TB.28, 33 Whole-genome sequencing holds promise for revolutionizing the predictive power of genotypic drug susceptibility test,34 but cost, throughput, facility requirement, ba…